Featured Studies Results

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/314/neptune-using-parp-inhibitors-before-surgery-in-localized-prostate-cancer

Clinicaltrials.gov identifier:
NCT05498272 (https://clinicaltrials.gov/show/NCT05498272)

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

---

Study of the Drug Sovilnesib in People with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/308/study-of-the-drug-sovilnesib-in-people-with-ovarian-cancer

Clinicaltrials.gov identifier:
NCT06084416 (https://clinicaltrials.gov/show/NCT06084416)

Treatment
Treatment study for people with platinum-resistant ovarian cancer

---

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study

Clinicaltrials.gov identifier:
NCT05417594 (https://clinicaltrials.gov/show/NCT05417594)

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

---

A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer

Clinicaltrials.gov identifier:
NCT05720039 (https://clinicaltrials.gov/show/NCT05720039)

Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer

---

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

https://www.facingourrisk.org/research-clinical-trials/study/175/niraparib-before-surgery-in-treating-patients-with-high-risk-localized-prostate-cancer-and-dna-damage-response-defects

Clinicaltrials.gov identifier:
NCT04030559 (https://clinicaltrials.gov/show/NCT04030559)

Treatment
High-risk localized prostate cancer

---

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib

Clinicaltrials.gov identifier:
NCT04550494 (https://clinicaltrials.gov/show/NCT04550494)

Treatment
Treatment study for people with advanced solid tumors

---

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

https://www.facingourrisk.org/research-clinical-trials/study/210/treating-metastatic-prostate-cancer-with-chemotherapy-or-parp-inhibitor-in-people-with-mutations-cobra

Clinicaltrials.gov identifier:
NCT04038502 (https://clinicaltrials.gov/show/NCT04038502)

Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

---

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra

Clinicaltrials.gov identifier:
NCT04644068 (https://clinicaltrials.gov/show/NCT04644068)

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer

---

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

https://www.facingourrisk.org/research-clinical-trials/study/129/olaparib-in-treating-patients-with-metastatic-biliary-tract-cancer-with-aberrant-dna-repair-gene-mutations

Clinicaltrials.gov identifier:
NCT04042831 (https://clinicaltrials.gov/show/NCT04042831)

Treatment
Treatment study for people diagnosed with metastatic biliary tract (bile duct) cancer and who have an inherited or tumor mutation in ATM, BRCA 1/2, BRIP1, CHEK2, RAD51C, RAD51D, PALB2, PTEN, NBN and others

---